Degenerative eye disease. At Irccs Sacro Cuore Don Calabria, experiments with liquid retina on humans will soon be carried out

by Endrius Salvalaggio

Hospitals conducting studies on a possible treatment for degenerative diseases of the eye are the Italian Institute of Technology in Milan, Clinic San Martino in Genoa, and Irccs Sacro Cuore Don Calabria in Negrar. Grazia Pertile coordinator for Negrar’s IRCCS: “The animal results are excellent and lay a solid foundation for the next steps. First human trials between 2025-2026.” I study

July 22 Retinitis pigmentosa is a degenerative disease that leads to the destruction of photoreceptors and light-sensitive cells of the retina. It manifests itself in different severity and at a variable age but the first symptoms usually appear at a young age and can lead to complete blindness. On the other hand, age-related macular degeneration occurs at a later age and affects only the central part of the retina. Severely ill patients cannot see details, so they have great difficulty reading and recognizing people’s faces. These diseases, which afflict hundreds of millions of people in the world, find a potential solution through the implantation of an artificial fluid retina.

The Irccs Sacro Cuore Don Calabria Hospital in Negra, the Italian Institute of Technology in Milan and the San Martino Polyclinic in Genoa, have successfully tested a prototype liquid retina on experimental models that reproduce advanced stages of retinitis pigmentosa, the same as the traditional retinal model. Reconstructive surgery is currently permitted. The successful outcome of the experiment, Posted in Nature’s nanotechnology — explains note — represents an additional approach to the feasibility of future clinical studies in humans.”

“It is precisely in the advanced stage of patients with retinitis pigmentosaA – The Eye Clinic Project Coordinator at Irccs Sacro Cuore Don Calabria Hospital in Negrar announces, Grace Bertil Those who have undergone reconstructive surgery. The results just obtained from the animal tests are excellent and lay a solid foundation for the next steps aimed at conducting the first tests in humans. We estimate that we are ready for 2025-2026. The liquid formulation of the prosthesis will allow for less traumatic and more effective interventions because the ICSI is able to reach a larger surface and establish close contact with the retinal cells that are still present.”
“The liquid retina is actually made up of nanoparticles that replace the damaged photoreceptors – explains the project coordinator – and these particles are suspended in a gel that allows you to create a kind of film. Only in the fall we will go to test formulations with different viscosities to determine the most suitable for the human eye. Therefore, the Department of Health will be required to obtain permission to proceed with dealing with humans.”

See also  Super sweet food to reduce weight and cholesterol

Being able to collaborate on the project, Pertile is keen to identify, “With people from different backgrounds that was a huge motivator. We are a very tight-knit working group that seeks to enrich the skills of others in order to advance the project as quickly as possible. After demonstrating that PV nanoparticles are effective even in the advanced stages of degenerative disease in which the retina is not present, The eye is not only completely free of photoreceptors, but has undergone profound modifications in the retinal circuits normally found in the inner layers, opening the door to applying this strategy to man.”

Andrews salvation

July 22 2022
© All Rights Reserved

Other articles in Science and Drugs








Online newspaper
health information.

QS Edizioni srl

B 12298010001

via Giacomo Peroni, 400
00131 – Rome

via Vittore Carpaccio, 18
00147 Rome (RM)

site manager

Cesar Vasari

managing editor
Francesco Maria Avito

Ernesto Rodriquez

Copyright 2013 © QS Edizioni srl. All rights reserved
– VAT number 12298601001
– Registration in ROC n. 23387
Registration at the Court of Rome n. 115/3013 on 05/22/2013

All rights reserved.
privacy policy

Leave a Reply

Your email address will not be published. Required fields are marked *